Biovest International, Inc. Retains Ferghana Partners to Evaluate Strategic Transactions

Published: May 16, 2012

TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB:ABPI), today announced that Biovest has retained Ferghana Partners as the Company’s strategic transaction advisor to evaluate/implement creative financings and partnering opportunities on a regional or global basis for BiovaxID®, its late-stage personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma.

Back to news